Results 201 to 210 of about 711,937 (246)
Some of the next articles are maybe not open access.
Reviews in Medical Virology, 2019
In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a rare opportunistic infection mostly seen in AIDS patients, was ...
D. Focosi, M. Tuccori, F. Maggi
semanticscholar +1 more source
In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a rare opportunistic infection mostly seen in AIDS patients, was ...
D. Focosi, M. Tuccori, F. Maggi
semanticscholar +1 more source
Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.
New England Journal of Medicine, 2019Treatment of PML with Nivolumab A patient with severe idiopathic lymphopenia and progressive multifocal leukoencephalopathy had T-cell exhaustion and high expression of immune checkpoint markers.
O. Walter +8 more
semanticscholar +1 more source
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
New England Journal of Medicine, 2019Treatment of PML with Pembrolizumab A patient with variable immunodeficiency and progressive multifocal leukoencephalopathy was treated with five pembrolizumab infusions.
S. Rauer +7 more
semanticscholar +1 more source
Update on Progressive Multifocal Leukoencephalopathy
Current Neurology and Neuroscience Reports, 2012Progressive multifocal leukoencephalopathy (PML) is a severe, often fatal, opportunistic viral infection of the central nervous system that is mainly seen in the context of AIDS and certain monoclonal immune-suppressive therapies. The causative agent, a polyoma virus, named JC virus infects only humans and there is no animal model for PML.
Israel, Steiner, Joseph R, Berger
openaire +2 more sources
Annals of Neurology, 2019
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.
Gloria Dalla Costa +11 more
semanticscholar +1 more source
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.
Gloria Dalla Costa +11 more
semanticscholar +1 more source
Viruses and Progressive Multifocal Leukoencephalopathy
New England Journal of Medicine, 1972There has recently been an increasing interest in the relation between viruses and chronic degenerative diseases of the brain. Within the past few years, measles virus has been found to be associated with subacute sclerosing panencephalitis and transmissible agents have been isolated from patients with Kuru and Creutzfeldt—Jakob disease (spongiform ...
P H, Black, M S, Hirsch
openaire +2 more sources
The spectrum of progressive multifocal leukoencephalopathy: a practical approach
European Journal of Neurology, 2019John Cunningham virus (JCV) infection of the central nervous system causes progressive multifocal leukoencephalopathy (PML) in patients with systemic immunosuppression.
T. Bartsch +6 more
semanticscholar +1 more source
Progressive multifocal leukoencephalopathy and natalizumab
Journal of Neurology, 2011Natalizumab (TYSABRI(®)), a specific α4-integrin antagonist, is approved as a second-line treatment of relapsing-remitting MS (RRMS) patients who fail therapy with interferons or as first-line treatment of patients with highly active relapsing-remitting disease. Since the market introduction of natalizumab as a monotherapy in July of 2006, 111 cases of
Kerstin, Hellwig, Ralf, Gold
openaire +2 more sources
Natalizumab and Progressive Multifocal Leukoencephalopathy
New England Journal of Medicine, 2005The Brief Reports on natalizumab were referred to Biogen Idec, the manufacturer, which offers the following response: After learning of one confirmed and one suspected case of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, Biogen Idec and Elan quickly notified the Food and Drug Administration (FDA) and other ...
Burt, Adelman +2 more
openaire +2 more sources
Progressive Multifocal Leukoencephalopathy
New England Journal of Medicine, 1961IN the course of the regular post-mortem examination of the brains of patients coming to autopsy at the Massachusetts General Hospital, my attention has been called in recent years to an unusual disorder of the cerebral white matter with distinctive features unfamiliar to me and my colleagues from our own experience or that of others.
openaire +3 more sources